Answer:
c. credit card bill
Explanation:
A credit card bill is a liability. It is a debt owned by the business to be paid within an accounting period. A credit card reflects authorization by the credit card company of a line of credit for the buyer with predetermined interest rates and payment terms- hence the term credit card. Most companies waive interest charges on the line of credit if the buyer pays its balance in full each month.
Once a credit is established with a credit card company or bank, the customer does not have to open an account with each store . Customers using these credit cards can make single monthly payments to different creditors and can defer their payments.
<em><u>Deffered payments </u></em> are a liability for a customer and need to be paid within the accounting period.
The formula for the receivables turnover ratio is net credit sales divided by average accounts receivable.
<h3>What is receivable turnover ratio?</h3>
The receivable turnover ratio is what measure the number of times over a given period that a company collects its average account.
It is the number of times per year that a business collects its average accounts receivable.
Hence, the formula for the receivables turnover ratio is net credit sales divided by average accounts receivable.
Learn more about receivables turnover ratio here : brainly.com/question/24849094
#SPJ1
Answer:
(DR) Cash $4,895,980; (CR) Bonds Payable $4,000,000; (CR) $895,980
Explanation:
The problem only requires the journal entry of the issuance of the bonds on January 1, 2016.
Simply <u>debit "Cash"</u> for the amount of the price which is $4,895,980.
Then <u>ALWAYS credit "Bonds Payable"</u> on its issued value of $4,000,000.
Now, since the cash price is greater than the issued value, the difference of $895,980 will be called as "Premium on Bonds Payable" and it will be credit.
So the entry would look like this:
(DR) Cash $4,895,980
(CR) Bonds Payable $4,000,000
(CR) Premium on Bonds Payable $895,980
Answer:
0.9; 100 million; 90 million; 2,143
Explanation:
The new fuel's price change has a standard deviation that is 50% greater than price changes in gasoline futures prices.
So, if standard deviation of future prices is taken as '1' then for spot price it will be 50% higher, i.e 1.5
The hedge ratio:
= Correlation × (standard deviation of spot price ÷ Standard deviation of future prices)
= 0.6 × (1.5 ÷ 1)
= 0.9
The company has an exposure of 100 million gallons of the new fuel.
Gallons in future gasoline:
= Hedge ratio × 100 million gallons of the new fuel
= 0.9 × 100
= 90 million
Each contract is on 42,000 gallons, then
Number of gasoline futures contracts should be traded:
= 90,000,000 ÷ 42,000
= 2,142.9 or 2,143
I can help with question two, but not question three.
The answer to question two is that biotech companies are part of the global industry from day one. Because capital is global, diseases know no borders, people are mobile, and you can get science anywhere in the world, there is an immediate competition with all other bioscience companies in the world.
In other words, when you start a biotech company in the US, you are immediately competing with biotech companies in Japan, the UK, etc. because you're all competing for the same capital, the same consumers, the same pharmacies, etc.
My best guess for question three is just that regulations are always important for global businesses (or really any business in general) as they protect both the businesses, the employees, and the consumers. In the case of biotech businesses, they protect people from false advertising of the benefits of products for example.
Hope this helps!
